+1 (218) 451-4151 info@writersnest.org
Select Page

The purpose of this paper is to discuss healthcare financing in America, as it relates to a case study about End Stage Renal Disease (ESRD). I will discuss the major reimbursement mechanisms for ESRD. Additionally, I will provide the organization’s point of view about the economics of providing ESRD treatment. I will share options and potential trade-offs related to cost of treatment, quality of treatment, and access to treatment. Finally, I will discuss the ethical implications of resulting treatment options based on cost evaluation.
Reimbursement Mechanisms
In 1972, Medicare coverage for beneficiaries and individual under 65 years of age was spurred on by economic and political forecasts. The support for ESRD reimbursement was due to the belief that the kidney transplant would become a routine practice and dialysis would become more obsolete (Munn-Short, 2008). Unfortunately the expectation was not met, as in 2006 there were over 65,000 beneficiaries on dialysis and waiting for a kidney transplant. In 2003 the Medicare Modernization Act mandated the first revision to the reimburs…
… middle of paper …